UBS Group
MGNX icon

UBS Group’s MacroGenics MGNX Stock Holding History

UBS Group’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$65.8K – 10220
2024
Q3 		$65.8K Hold
20,000
– – ﹤0.01% 6646
2024
Q2 		$85K Buy
+20,000
New +$195K ﹤0.01% 6305

Other funds holding MGNX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

UBS Group's MGNX Position: Q2 2026 in Review

UBS Group reduced its MacroGenics (MGNX) stake by 86% in Q2 2026, selling an estimated $962K and leaving 41,835 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #6813.

UBS Group first reported a position in MGNX in Q4 2014 and has held it in 47 quarters since. The position peaked at $3.8M in Q1 2024. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • UBS Group held 41,835 shares of MacroGenics worth $193K as of Q2 2026.
  • UBS Group sold 254,251 MacroGenics shares in Q2 2026, an estimated $962K.
  • MacroGenics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6813 holding.
  • UBS Group first reported a position in MacroGenics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's MacroGenics position peaked at $3.8M in Q1 2024.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.